News
Dear users of the NCP Flanders website,
As of today, the NCP Flanders website has a new look aimed at providing a more user-friendly experience. While the content and services available on the website remain unchanged, the fresh new layout is designed to enhance navigation and accessibility.
Pages specifically related to one of the programmes we advise on can be easily identified by their colour:
The different features such as news, events, info sheets, the video corner and partner searches remain the same and are still easy to find on the top of the page.
We would also like to take this opportunity to invite you check and – if appropriate - update your profile to make sure that you receive information tailored to your specific needs.
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
ESA Space Solutions has opened a call for proposals on space-enabled solutions for resilient electricity grids, in collaboration with ENTSO-E. The call supports proof-of-concept studies and pilot projects that address challenges in grid resilience and operational continuity.
Read moreThe Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.
Read moreThe launch of the 2027 calls for proposals under the Defence-related Research Action (DEFRA) programme has been postponed until Spring 2027. As a result, the information days initially scheduled for 23 and 24 November 2026 will also be postponed. A revised timeline will be communicated as soon as it becomes available.
Read moreThe European Partnership for Personalised Medicine (EP PerMed) is about to launch the joint transnational call 2027 (JTC2027) “Cell and Gene Therapy for Personalised Medicine”. The call opens on 4 November 2026.Proposals must focus on the development and validation of an innovative and novel cell and gene therapy for...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
